Interlaboratory variation in factor VIII:C inhibitor assay results is sufficient to influence patient management: data from the UK national quality external assessment scheme for blood coagulation.
New fundamentals in hemostasis.
Versteeg HH, Heemskerk JW, Levi M, Reitsma PH.
Physiol Rev. 2013 Jan;93(1):327-58. doi: 10.1152/physrev.00016.2011.
Coagulation Testing in the Core Laboratory.
Winter WE, Flax SD, Harris NS.
Lab Med. 2017 Nov 8;48(4):295-313. doi: 10.1093/labmed/lmx050.
Coagulation Inhibitor Potential: a study of assay variables.
Andresen MS, Abildgaard U.
Thromb Res. 2005;115(6):519-26. doi: 10.1016/j.thromres.2004.11.018. Epub 2004 Dec 16.
Advances in monitoring anticoagulant therapy.
Božič Mijovski M.
Adv Clin Chem. 2019;90:197-213. doi: 10.1016/bs.acc.2019.01.005. Epub 2019 Feb 21.
Pearls and pitfalls in factor inhibitor assays.
Adcock DM, Favaloro EJ.
Int J Lab Hematol. 2015 May;37 Suppl 1:52-60. doi: 10.1111/ijlh.12352.
Continuous infusion of coagulation factor concentrates during intensive treatment.
Holme PA, Tjønnfjord GE, Batorova A.
Haemophilia. 2018 Jan;24(1):24-32. doi: 10.1111/hae.13331. Epub 2017 Sep 5.
[Acquired coagulant factor inhibitors].
Nogami K.
Rinsho Ketsueki. 2015 Feb;56(2):160-8. doi: 10.11406/rinketsu.56.160.
Nature of von Willebrand factor: a new assay and a specific inhibitor.
Sarji KE, Stratton RD, Wagner RH, Brinkhous KM.
Proc Natl Acad Sci U S A. 1974 Aug;71(8):2937-41. doi: 10.1073/pnas.71.8.2937.
High Titer of Acquired Factor V Inhibitor Presenting with a Pseudo-deficiency of Multiple Coagulation Factors.
Nakata K, Ueda S, Matsunaga H, Mima F, Ueda H, Yoshioka A, Kaneko S, Maruo K, Morris S, Yonemoto S, Hayashi D, Fujii N, Narahara H, Inui Y, Kawata S.
Intern Med. 2018 Feb 1;57(3):393-397. doi: 10.2169/internalmedicine.9150-17. Epub 2017 Nov 1.
Autoantibodies to coagulation factors: from pathophysiology to diagnosis and therapy.
Cugno M, Gualtierotti R, Tedeschi A, Meroni PL.
Autoimmun Rev. 2014 Jan;13(1):40-8. doi: 10.1016/j.autrev.2013.08.001. Epub 2013 Aug 14.
